Cantex Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cantex Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10836
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cantex Pharmaceuticals Inc (Cantex Pharmaceuticals), formerly ParinGenix Inc is a clinical stage biopharmaceutical company. The company discovers and develops proprietary pharmaceuticals for the treatment of cancers and other disorders. Its pipeline products include CX-01 a proprietary combination of disulfiram and copper that is in Phase II clinical trial for the treatment of recurrent glioblastoma; and completed Phase 1 trial in metastatic prostate cancer and breast cancer. Cantex Pharmaceuticals also develops CX-01 a polysaccharide used for the treatment of acute myeloid leukemia (AML), traumatic brain injury and other blood disorders. The company offers its products across the US. Cantex Pharmaceuticals is headquartered in Weston, Florida, the US.

Cantex Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Cantex Pharma Raises Additional USD0.3 Million in Financing Round 10
Cantex Pharma Raises Additional USD1.6 Million in Financing Round 11
Cantex Pharma Raises USD0.7 Million in Financing Round 12
Paringenix Raises US$0.7 Million In Venture Financing 13
Acquisition 14
Shenzhen Hepalink Pharma to Invest USD30 Million in Cantex Pharma 14
Cantex Pharmaceuticals Inc – Key Competitors 16
Cantex Pharmaceuticals Inc – Key Employees 17
Cantex Pharmaceuticals Inc – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Clinical Trials 19
Oct 12, 2017: Lenox Hill Hospital participates in clinical research study to test investigational treatment for recurrent brain cancer 19
May 01, 2017: Cantex Pharmaceuticals Announces Initiation of Phase 2 Clinical Development for CX-02 in Recurrent Glioblastoma 20
Apr 04, 2017: Cantex Pharmaceuticals Announces Poster Presentation at AACR Annual Meeting 2017 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cantex Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Cantex Pharma Raises Additional USD0.3 Million in Financing Round 10
Cantex Pharma Raises Additional USD1.6 Million in Financing Round 11
Cantex Pharma Raises USD0.7 Million in Financing Round 12
Paringenix Raises US$0.7 Million In Venture Financing 13
Shenzhen Hepalink Pharma to Invest USD30 Million in Cantex Pharma 14
Cantex Pharmaceuticals Inc, Key Competitors 16
Cantex Pharmaceuticals Inc, Key Employees 17

List of Figures
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Cantex Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cardiovascular Systems Inc (CSII):企業の財務・戦略的SWOT分析
    Summary Cardiovascular Systems Inc (CSI) is a medical device company that develops and commercializes products for the treatment of peripheral and coronary vascular disease. The company's products include peripheral orbital atherectomy system, coronary orbital atherectomy system, crowns, and accesso …
  • Ontario Power Generation Inc-エネルギー分野:企業M&A・提携分析
    Summary Ontario Power Generation Inc. (OPG) is an electricity generating company, fully owned by the Government of Ontario. It carries out the generation and sale of electricity in Ontario. The company generates electricity by utilizing various sources of energy including nuclear, hydroelectric, bio …
  • Neste Corp (NESTE):石油・ガス:M&Aディール及び事業提携情報
    Summary Neste Corp (Neste) is an oil refining and marketing company that offers advanced, clean traffic fuels besides shipping and engineering services. The company produces and sells gasoline; diesel fuel; aviation fuel; bunker fuel; heating oil; light and heavy fuel oil; base oils; gasoline compon …
  • Hong Leong Group:企業の戦略・SWOT・財務情報
    Hong Leong Group - Strategy, SWOT and Corporate Finance Report Summary Hong Leong Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Meridian Energy Limited:企業の戦略・SWOT・財務情報
    Meridian Energy Limited - Strategy, SWOT and Corporate Finance Report Summary Meridian Energy Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Boston Scientific Corporation:企業のM&A・事業提携・投資動向
    Boston Scientific Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Boston Scientific Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Blueprint Medicines Corp (BPMC):企業の財務・戦略的SWOT分析
    Summary Blueprint Medicines Corp (Blueprint Medicines), formerly Hoyle Pharmaceuticals Inc, discovers and develops precision therapies for the treatment of cancers and rare diseases. The company offers AYVAKIT (avapritinib) medicine to treat gastrointestinal stromal tumor (GIST); and GAVRETO (pralse …
  • Response Biomedical Corp:医療機器:M&Aディール及び事業提携情報
    Summary Response Biomedical Corp (Response Biomedical) focuses on the research, development, manufacture and marketing of diagnostic technologies for the point-of-care (POC), central-lab testing and on-site environmental testing markets. It offers Cardiovascular tests such as Troponin-I, Myoglobin, …
  • MedMira Inc (MIR)-医療機器分野:企業M&A・提携分析
    Summary MedMira Inc (MedMira) is a medical device company that offers rapid diagnostics and technology solutions. The company offers products in areas of HIV, H. pylori, syphilis, multiplex, miriad rvf toolkit, and tissue and eye banks. It offers testing products for HIV, H. Pylori and syphilis, bes …
  • Telormedix SA-製薬・医療分野:企業M&A・提携分析
    Summary Telormedix SA (Telormedix) is a biopharmaceutical company. The company develops and provides immune drugs for the treatment of cancer and other infectious diseases. It offers products such as TMX-201, TMX-202 and vesimune (TMX-101). Its vesimune (TMX-101) provides treatment for superficial b …
  • Zeltiq Aesthetics Inc (ZLTQ):企業の財務・戦略的SWOT分析
    Summary Zeltiq Aesthetics Inc (Zeltiq), formerly Juniper Medical Inc, a subsidiary of Allergan Plc, is a medical technology company that develops and commercializes non-invasive products for the reduction of fat, selectively. The company offers CoolSculpting system, which uses proprietary controlled …
  • Galectin Therapeutics Inc.:企業のM&A・事業提携・投資動向
    Galectin Therapeutics Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Galectin Therapeutics Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Downer EDI Ltd (DOW):企業の財務・戦略的SWOT分析
    Downer EDI Ltd (DOW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • DowDuPont Inc (DWDP):企業の財務・戦略的SWOT分析
    DowDuPont Inc (DWDP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Novartis India Ltd (500672):企業の財務・戦略的SWOT分析
    Summary Novartis India Ltd (Novartis), a subsidiary of Novartis AG, is a healthcare company that offers pharmaceuticals, generic medicine and eye care products. The company’s pharmaceutical division develops drugs in the therapeutic areas of bone and pain, calcium portfolio, gynecology, oncology and …
  • Breville Group Limited (BRG):企業の財務・戦略的SWOT分析
    Breville Group Limited (BRG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Aptuit LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Aptuit LLC (Aptuit) is a developer and manufacturer of pharmaceutical drug. The company offers drug design and discovery, IND enabling programs, integrated chemistry, manufacture and control and indigo. It drug discovery capabilities includes medicinal chemistry, computational chemistry, pha …
  • Kronos Incorporated:企業の戦略・SWOT・財務情報
    Kronos Incorporated - Strategy, SWOT and Corporate Finance Report Summary Kronos Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Anglo American Plc:企業の戦略・SWOT・財務情報
    Anglo American Plc - Strategy, SWOT and Corporate Finance Report Summary Anglo American Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Long Run Exploration Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Long Run Exploration Ltd (Long Run), formerly WestFire Energy Ltd, a subsidiary of Calgary Sinoenergy Investment Corp, is an oil and gas company that offers development and exploration of light oil. The company grows crude oil volumes within its diversified portfolio properties. Its oil expl …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆